Twelve weeks of combination Sovaldi and NS5A inhibitors without ribavirin was a reliable therapy with high rates of sustained virologic response for recurrent hepatitis C after liver transplantation, according to a study published in Hepatology.
“Liver recipients with HCV recurrence have always been considered as a difficult-to-treat population,” Pauline Houssel-Debry, MD, from the Pontchaillou University Hospital in France, and colleagues wrote. “Previous HCV treatment post-LT, progression of fibrosis on the graft, a high HCV viral load, and the immunosuppressive therapy implemented had originally prompted clinicians to choose treatment for 24 weeks with [ribavirin] in order to improve SVR12 rates. However, the availability of [direct-acting antivirals] should change these dogmas.”
The study comprised 512 LT recipients treated with Sovaldi (sofosbuvir, Gilead Sciences) and NS5A inhibitors with or without ribavirin. Most patients had HCV genotype 1 (70.1%) while 18.2% were infected with genotype 3.